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Introduction
 Meningiomas are  neoplasms ar is ing from 
meningothelial cells of the meninges and account for 
about 16-30% of intracranial neoplasms. The WHO 2007 
grading system categorizes meningiomas into gradeI 
(90%), grade II (7%), and grade III (3%).
 Afshin Moradi et al. (2008) reviewed intracranial 
lesions that underwent biopsy in Shohada Hospital in a 
10-year period between 1997 and 2006 and reported that 
meningiomas accounted for 378 out of 4885 (7.74%) 
studied specimens. Of these, 329 cases were grade I, 41 
cases grade II, and 8 cases grade III, according to the WHO 
2000 classification.
 The WHO grade I tumors are generally well-defined, 
slow in progress, and curable by surgery, whereas grade 
II lesions have ill-defined borders with a slow growth 
rate and greater probability of recurrence and grade III 
lesions have malignant histological features and require 
aggressive adjuvant therapy.
 We defined a group of tumors that show some degrees 
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Abstract
 Background: Meningiomas are the second most common primary intracranial tumors after gliomas. Epigenetic 
biomarkers such as DNA methylation, which is found in many tumors and is thus important in tumorigenesis 
can help diagnose meningiomas and predict response to adjuvant chemotherapy. We investigated aberrant O6- 
methyl guanine methyltransferase (MGMT) methylation in meningiomas. Materials and Methods: Sixty-one 
patients were classified according to the WHO grading, and MGMT promoter methylation status was examined 
via the methylation-Specific PCR(MSP) method. Results: MGMT promoter methylation was found in 22.2% of 
grade I, 35% of grade I with atypical features, 36% of grade II, and 42.9% of grade III tumors. Conclusions: 
There was an increase, albeit not statistically significant, in MGMT methylation with a rise in the tumor grade. 
Higher methylation levels were also observed in the male gender. 
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of anaplasia, which is insufficient for the diagnosis of 
meningioma grade II. In the WHO grading system, three 
out of the five criteria of increased cellularity, small cells 
with a high nuclear-to-cytoplasmic ratio, prominent 
nucleoli, patternless growth, and necrosis must be present 
for the definition of meningioma grade II (Louis et al., 
2007). We hypothesized that if a tumor fulfills fewer 
than three criteria and does not meet the criteria of grade 
two, it may be in a less differentiated grade than grade I 
tumors and named it”meningioma with atypical features 
(I /A)”. These tumors may be a source of the reported 
unpredictable behavior of meningiomas.
 There are numerous reports that show low-grade 
tumors (WHO grade I) behave like malignant ones and 
even occasionally metastasize to distant organs. Asiolis 
et al. (2007) reported a case of benign meningioma 
metastasizing to the lung twelve years after the resection 
of a primary intracranial tumor. Be Figueroa et al. 
(1999) described a metastatic transitional meningioma 
(WHO grade I) after tumor recurrence: the primary 
tumor, recurrence, and metastatic lesions had the same 
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morphology. In 2002, Ramakishnamurthy et al. (2002) 
reported an intraventricular meningioma with benign 
histology that spread through the cerebrospinal fluid 
pathways and the recurrence of the tumor also had the 
same benign morphology. Nakano et al. (2012) described 
a case of 34-year-old man with a bilateral parasagittal 
meningioma that developed pulmonary metastasis 
with the tumor histology of transitional (WHOgradeI) 
meningioma.
 Several genetic changes such as inactivation mutations 
in neurofibromatosis 2 gene (merlin) on chromosome 22q 
have been well-known in meningioma for many years 
(Perry et al., 2004), but there is currently a dearth of 
data on epigenetic changes. Although the importance of 
epigenetic alterations has opened a new era for a better 
recognition of tumorigenesis and there have been studies 
on such intracranial neoplasms as glioblastomas, there are 
only scant researches on small groups of meningiomas. 
Furthermore, most of these investigations have been 
performed on low-grade tumours.
 Epigenetic alterations include reversible heritable 
changes in the gene function without alteration in primary 
DNA sequences (Russo et al., 1996). There are four major 
epigenetic mechanisms affecting gene transcriptions 
in the human genome: chromatin modification (Li 
2002);histone code (Jenuwein, Allis 2001); micro RNAs 
(Sato et al., 2011) and DNA methylation (Bird 2002). DNA 
methylation is defined as the addition of the methylgroup 
to cytosine before guanine, which is carried out by DNA 
methyltransferase enzyme.
 The majority of CpG islands (CpG I) in an active gene 
are normally unmethylated.
 The methylation of selected CpG sites within a CpG 
I in the promoter of a gene is associated with decreased 
gene expression (Feinberg, Vogelstein 1983). CpG I 
is at least 200 bps stretch of DNA that contains a high 
frequency of CpG dinucleotide C+G content (above 50%) 
and an observed/expected CpG ratio of greater than 60% 
(Bird 1986). O6-methylguanine-DNA methyltransferase 
(MGMT) protein removes the alkyl group from the O6 
of guanine residue by transferring it to specific cytosine 
residue within the protein (Ludlum, 1990; Pegg et al., 
1995).
 Silencing of the DNA can damage repair genes 
by hypermethylation and the promoters of CpG I 
can contribute to tumorigenesis (Baylin, Herman 
2000). Previous reports have shown that MGMT 
hypermethylation occurs in many tumor types, including 
gliomas, large B-cell lymphomas, retinoblastomas, and 
cancers of the breast, lung, prostate, stomach, and colon 
(Herfarth et al., 1999; Wu et al., 2008; Hibi et al., 2009; 
Sharma et al., 2009). Many studies have observed a high 
frequency of MGMT methylation in tumors, but there are 
only a few studies on the status of MGMT methylation in 
meningiomas.
 The present study aims to evaluate the hyper 
methylation of MGMT promoter as an accessory tool, 
in addition to the tumor grade and proliferative indices, 
to predict the tumor behavior and response to alkylating 
chemotherapeutic agents with a view to a better patient 
management; comparison of the hypermethylation rates 
between the different grades and evaluation of its role 
in the tumor genesis and comparison of the degree of 
hypermethylation in meningiomas with atypical features 
with three well-established histological grades.
Materials and Methods
Tissue samples
 Paraffin-embedded blocks of meningiomas were 
collected from Department of Pathology , Shohada 
Hospital affiliated to Shahid Beheshti University of 
Medical Sciences (SBMU) between 1996 and 2010. All of 
the samples have been fixed in 10% buffered formalin,and 
embedded according to routine standards of pathology. All 
the samples have been prepared under the same protocol 
for fixation and embedding.Meningioma slides from each 
case were re-reviewed by three pathologists to confirm 
the histological diagnosis and revision of the grading 
in accordance with the WHO 2007 classification of the 
central nervous system tumors. The representative sample 
was selected by a pathologist. The meningioma samples 
comprised 9 benign (WHO grade I), 20 grade I/A (WHO 
grade I), 25 atypical (WHO grade II), and7 anaplastic 
(WHO grade III) tumors.
DNA extraction
 DNA methylation in the CpG I of MGMT gene was 
examined using the Methylation-Specific PCR (MSP) 
method. Each paraffin block was cut at 10µM (3-5 
sections) and collected in an autoclaved plastic tube. 
To avoid the cross-contamination of the samples, the 
Microtome Blade was carefully cleaned with xylene and 
ethanol. Genomic DNA was isolated from the tumor 
sections using QIAamp DNA FFPE Tissue Kit (QIAGEN, 
Germany) following the manufacturer’s instructions.
Bisulfite treatment
 The DNA extracted from the tumor samples was 
subjected to bisulfite treatment and DNA purification using 
the EpiTect Bisulfite (QIAGEN, Germany) in accordance 
with the manufacturer’s instructions. Two hundred ng 
bisulfite-modified DNAs from the same treatment were 
used as the template for PCR. The modified DNA was 
amplified using primers specific for either methylated or 
unmethylated MGMT promoter sequences. The primers 
were used in earlier reports (Bello et al., 2004) and are 
listed in Table 1.
Methylation-specific PCR
 Amplifications were performed in a 25-μl reaction 
volume and contained 1.5 mM of MgCl2, 1.5 units of 
HotStarTaq Plus DNA Polymerase (QIAGEN, Germany), 
Table 1. PCR Primer Sequences (Bello et al., 2004) 
 Primer set Primer sequence Product size
Unmethyl  93bps
 MGMT Sense 5´-TTTGTGTTTTGATGTTTGTAGGTTTTTGT-3´ 
 MGMT Antisense 5´-AACTCCACACTCTTCCAAAAACAAAACA-3´ 
Methyl  81bps
 MGMT Sense 5´-TTTCGACGTTCGTAGGTTTTCGC-3´ 
  MGMT Antisense 5´-GCACTCTTCCGAAAACGAAACG-3´
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200 μM of dNTPs, 10 pmol of each primer, and 200 ng 
of bisulfite-treated DNA. 
 PCR conditions were as follows: one step at 95°C for 
5 minutes; 40 cycles at 94°C for 45 seconds; 59°C for 45 
seconds; 72°C for 45 seconds; and final extension at 72°C 
for 10 minutes.
 Unmethylated and methylated DNA (QIAGEN, 
Germany) served as negative and positive controls, 
respectively. A negative control without DNA was 
also included and each PCR was repeated twice. The 
hypermethylation status of MGMT promoter CpG I was 
determined through an analysis of the PCR products in 
12% polyacrylamide gel after silver nitrate staining.
 This study was approved by Cancer Research Center 
Ethics Committees of Shahid Beheshti University of 
Medical Sciences (8730-111-1-90).
Statistical analysis
 In this study, two logistic regression models were 
conducted to assess the effect of the tumor grade on 
methylation status. In model I, the tumor grade was 
considered a categorical variable with four categories 
(I, I/A, II, and III), by using indicator variables for the 
various categories (grade 1 was regarded as the reference 
group). In model II, the grade of the tumor was treated as 
an ordered variable by coding the categories as follows: 
grade=1 if grade I; grade =1.5 if grade I/A; grade=2 if 
grade II; and grade =3 if grade III. Thereafter, the two 
models were compared to test whether the ordered scale 
provided an adequate fit by comparison with the use of 
the indicator variables. Furthermore, unadjusted binary 
logistic regression models were conducted to assess the 
association between the patients’ characteristics and 
morphological features and MGMT gene methylation 
status.
Results 
Study population
 Sixty-one patients were recruited into this study. The 
patients’ characteristics are summarized in Table 2. The 
result of the MSP analysis for MGMT gene are shown 
in Table 4. A total of 21 of the 61 samples (34.40%) 
showed hypermethylation.The median age of the patient 
was 48.00 years with a range of 2-80 years.MGMT 
promoter hypermethylation was detcted in all grades 
of meningiomas.there were 31 (50.80%) female and 30 
(49.20%) male patients.
Results of methylation on meningiomas
 The frequency of MGMT methylation in our study was 
22.22% (2/9) in grade I, 35% (7/20) in grade I/A, 36% 
(9/25) in grade II, and 42.85% (3/7) in grade III, which 
indicated that MGMT was more frequently methylated in 
grade I/A than gradeI and showed that MGMT methylation 
frequency in grade I/A was more similar to grade II than 
grade I.
Association between methylation status and tumour grade
 Table 3 depicts the results of the logistic regression 
analyses to assess the effect of the tumor grade on 
methylation status. Using the likelihood ratio test, the 
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Table 2. Patient Characteristics  
Characteristics Patients (n=61)
Age, years 
 All patients (n=61) 
  Mean ±SD 48.41±15.20
  Median (range) 48.00 (2-80)
 Female (n=31) 
  Mean ±SD 44.84±13.19
  Median (range) 46.00 (17-75)
 Male (n=30) 
  Mean ±SD 52.10±16.45
  Median (range) 49.50 (2-80)
Gender, no. (%) 
 Female 31 (50.80%)
Location of tumor, no. (%) 
 Lateral convexity &sagittal sinus 51 (83.61%)
 Sphenoid ridge & base of skull   7 (11.47%)
 Spinal   3 (4.92%)
MGMT status, no. (%) 
 Methylated 21 (34.40%)
 Unmethylated 40 (65.60%)
Grade of meningioma, no. (%) 
 Grade I   9 (14.75%) 
  Methylated   2
  Unmethylated   7
 Grade I/A 20 (32.79%)
  Methylated   7
  Unmethylated 13
 Grade II 25 (40.98%)
  Methylated   9
  Unmethylated 16
 Grade III   7 (11.48%)
  Methylated   3
  Unmethylated   4
Table 3. The Results of Logistic Regression Analyses
Model (1) B S.E. Wald df Sig. OR  95% CI for OR 
       Lower  Upper
  Constant -1.25 0.8 2.44 1 0.12 0.29  
  Grade    0.82 3 0.84   
  Grade I/A (vs. grade I) 0.63 0.93 0.47 1 0.49 1.88 0.3  11.64
  Grade II (vs. grade I) 0.68 0.9 0.56 1 0.45 1.97 0.33  11.57
  Grade III (vs. grade I) 0.96 1.11 0.76 1 0.38 2.62 0.3  22.1
Model (2)        
  Constant -1.34 0.93 2.08 1 0.15 0.26  
  Grade 0.38 0.48 0.62 1 0.43 1.47 0.57  3.79
Model I: The grade of disease was considered a categorical variable with four categories (I, I/A, II, and III), by using indicator variables for the various categories (grade 
1 was considered a reference group), Model II: The grade of disease was treated as an ordered variable by coding the categories, as follows: grade =1 if grade I; grade=1.5 
if grade I/A; grade=2 if grade II; and grade=3 if grade III.
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model that related the tumor grade on an ordered scale 
to the incidence of methylation provided an adequate fit 
as compared to the use of the indicator variables (p value 
=0.88, Table 3). According to model II, the tumor grade 
was not significantly associated with methylation status, 
although higher risks of methylation were observed in 
the expected directions (p value =0.43). Based on model 
II, the odds ratios for grades I/A, II, and III (compared 
to grade I) were 1.21, 1.46, and 2.14, respectively (Table 
3). In the unadjusted binary logistic regression models, 
only gender showed statistically significant differences 
in promoter methylation frequency (M=3, 95%CI=0.99-
9.07; p value=0.046) (Table 4).There was no independent 
statistical correlation between methylation status and 
patients’ age, tumor location, mitotic count, nucleo-
cytoplasmic ratio, prominent nucleolus, hypercellularity, 
necrosis, and tumor size. The logistic regression analysis 
showed that there were no differences in promoter 
MGMT methylation frequencies between the different 
meningioma grades.
Discussion
Many studies have shown that DNA methylation 
profiles vary between normal tissues and derived tumors 
and between different tumor types. Aberrant DNA 
hypermethylation at the promoter region DNA repair gene 
contributes to the progression of some cancers (Herfarth 
et al., 1999; Wu et al., 2008; Hibi et al., 2009; Sharma et 
al., 2009). We used MSP (Methylation-Specific PCR) to 
evaluate the status of the promoter methylation of MGMT 
gene in the different grades of meningioma tumors. 
There are several case reports of benign meningiomas 
(WHO grade I) disseminating through the cerebrospinal 
fluid or even metastasizing to distant organs, especially 
the lung. As mentioned previously, we believe that 
even minor degrees of anaplasia may have some effects 
on the tumor behavior and we defined such cases as 
meningioma grade I with atypical features (grade I/A).
The status of MGMT methylation in meningioma grade 
I/A in comparison with the WHO grades I, II, and III of 
meningiomas was the major subject of this study. The 
methylation status of MGMT promoter might be a useful 
predictor marker alongside morphological features for 
a better characterization of the meningioma grades and, 
thus, predict responsiveness to alkylating agents such as 
carmustine, lumastin, and temozolomide.
The frequency of MGMT methylation in our study was 
22.22% (2/9) in grade I, 35% (7/20) in grade I/A, 36% 
(9/25) in grade II, and 42.85% (3/7) in grade III, which 
indicated that MGMT was more frequently methylated in 
grade I/A than gradeI and showed that MGMT methylation 
frequency in grade I/A was more similar to grade II 
than grade I. No significant differences were, however, 
observed in the methylation status between grade I and 
grade I/A and nor was there any significant association 
between MGMT methylation frequency and different 
tumor grades.
Our logistic regression models revealed increased 
odds for the frequency of MGMT methylation from 
low- to high-grade meningiomas. The increase in the 
methylation rate in the higher-grade tumors may be one 
of several genetic and epigenetic changes responsible 
for neoplasm upgrading. There is a paucity of data in the 
existing literature on the status of MGMT methylation 
of meningiomas. Bello et al. (Bello et al., 2004) detected 
aberrant MGMT methylation in 13%,26%, and 0% 
of grade I,II and III tumors. In another study Yanli liu 
et al. (2005) reported the status of aberrant MGMT 
methylation in 6% ( 1/16) of grade I,5% (1/19) of grade 
II, and 8%(1/13) of grade III tumors. In the Robles et al. 
(2008), none of the meningioma samples showed MGMT 
promoter methylation. In the present study, the frequency 
of MGMT methylation was higher than that previously 
reported. It is worthy of note that the status of MGMT 
methylation can vary for a particular tumor. For example 
in glioblastoma patients, previous studies have reported 
rates of 24%,33%,34%,35%, 40%,45%,47.5%,53%,68%, 
and 70% for MGMT promoter methylation (Esteller et 
al., 2000; Hegi et al., 2004; Hegi et al., 2005; Brandes et 
al., 2008; Dunn et al., 2009; Costa et al., 2010; Rivera et 
al., 2010; Sciuscio et al., 2011; Havik et al., 2012; Tang 
et al., 2012). It is possible that variability in the rates of 
promoter-region gene hypermethylation in meningioma 
tumors may be influenced by race, high fat food diet, 
polymorphism, smoking, dietary variables, and other 
environmental exposures. Enokida et al. (2005) observed 
that methylation of GSTP1 was significantly high in 
Caucasians and Asians in prostate cancer. In prostate 
cancer, Kwabi-Addo et al. (2011) observed significant 
differences in methylation levels in five genes in African 
Americans in comparison with Caucasian samples. 
Wallace et al. (2010) reported that African Americans 
had lower levels of ERα and SFRP1methylation than did 
Caucasians and Hispanics, and higher RBC folate levels 
were associated with higher levels of the methylation of 
the genes. Accordingly, the utilization of MGMT as ethnic-
sensitive biomarkers may be considered for meningiomas.
Brait et al.(2009)demonstrated a statically significant 
association between RARβ2 promoter methylation and 
Table 4. Results of Unadjusted Binary Logistic 
Regression Analyses for Associations Between Subject 
Characteristics and Methylation Status1
Characteristics2 Odds ratio (95%CI) P value
Age, years (vs. <50)   
 ≥ 50 years  1.11 (0.38-3.20) 0.84
Male (vs. Female) 3.00 (0.99-9.07) 0.046*
Mitoses (vs. <4)  0.86
 4-20 0.70 (0.19-2.60) 
 >20 0.87 (0.07-10.43) 
N/C ratio (vs. Normal)  
 High 1.50 (0.30-7.43) 0.62
Nucleolus (vs. Negative)  
 Positive 0.93 (0.30-2.83) 0.9
Cellularity (vs. Low)  
 High 0.32 (0.06-1.60) 0.16
Necrosis (vs. Negative)  
 Positive  2.00 (0.61-6.59) 0.25
 Tissue size 1.17 (0.98-1.40) 0.07
1 Methylation status: Methylated and not methylated, 2 The unadjusted odds ratios 
were calculated for each variable; the reference group for each variable is given in 
parentheses. For example, the odds of methylation in the men is 3 times the odds 
for the females (p value =0.046).
Asian Pacific Journal of Cancer Prevention, Vol 15, 2014 37
DOI:http://dx.doi.org/10.7314/APJCP.2014.15.1.33
MGMT Gene Promoter Methylation in Meningiomas of Grades I, II, and III
a high fatty food intake. The Leng et al. (2011) showed 
that haplotype containing A allele of MGMT promoter-
enhancer SNP could serve as apredictorfor the methylation 
rate along with the process of lung carcinogenesis. Liu 
et al. (2010) demonstrated that male smokers had more 
MGMT methylation than did non-smokers. Elsewhere, a 
positive correlation was shown between environmental 
tobacco smoke and MGMTmethylation by Brait et al. 
(Brait et al., 2009; Leng et al., 2011).
We found that our male patients had significantly 
higher levels of MGMT methylation than did the females. 
The impact of gender on DNA methylation has been 
previously studied. For instance, THBS1,TIMP3,E-
cadherin,DAP-kinase, RASST1A, MTHFR, and some 
other genes have been reported to be more frequently 
methylated in male patients than in females (Kang et al., 
2003; Sarter et al., 2005). Wu et et al. (2010) observed that 
tumors with p53 mutation in males contained higher levels 
of MGMT methylation than those in females. Lai et al. 
(2009) reported lower rates of ER and MGMT methylation 
and lower risks for lung cancer in females and contributed 
it to β-estradiol hormone replacement therapy.
First and foremost among the limitations of the current 
study was its relatively small sample size. A larger sample 
size should provide accurate statistical analyses of the 
possible relationship between methylation status and 
grades of meningiomas.We suggest experiments on larger 
samples in each tumor grade. Larger studies are needed 
to validate the gender differences in MGMT methylation 
frequency between the different tumor grades. Insufficient 
information on the patients’ lifestyle such as smoking 
habits and fatty food intake and information on recurrence, 
treatment, and survival, which rendered the definition of a 
cancer grade-specific biomarker based on our observation 
difficult, was another major drawback. The strength of this 
study, however, lies in the fact that it is the first study of 
its kind to investigate MGMT methylation WHO grade 
I with atypical features in comparison with the WHO 
grades I,II, and III.
In summary, we analyzed and compared MGMT 
methylation between the WHO grade I/A and grades 
I,II, and III. We detected a linear increase, albeit not 
statistically significant, in MGMT methylation grade I, 
grade I/A, gradeII, and grade III. We also demonstrated 
a tendency for increase in the MGMT methylation rate 
in the process of anaplastic transformation and found 
a statistically significant association between MGMT 
methylation and the male gender in meningiomas. 
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